According to World Health Organization, only front line health workers will get the vaccine. The health body says the new measures are needed to ensure that the remaining stock of the vaccine is enough until more vaccines can be produced by Merck.
Only the people in danger of Ebola infection in
Uganda will receive the Ebola Merck Vaccine rVSV ZEBOV, according to a Global
According to World Health Organization, only
front line health workers will get the vaccine. The health body says the new
measures are needed to ensure that the remaining stock of the vaccine is enough
until more vaccines can be produced by Merck.
The Ebola Merck vaccine is one of the two
experimental vaccines that have been developed to prevent Ebola infection. The
vaccine was used in the 2014 West Africa Ebola outbreak and in the DRC
outbreak. It is the only Ebola vaccine that has proved to be 97.5 percent
effective in protecting people against Ebola.
In July, Merck spokesperson, Pam Eisele revealed in a
statement that the company had 245,000 1.0 Ml of the dose ready for shipment.
The amount of the vaccine still in stock has not been disclosed by Merck.
the company is expected to produce an additional 450,000 next year to help with
supply of the vaccine. At the moment the dosage of the vaccine has been reduced
from 1.0 ml to 0.5 ml.
Dr. Yonas Tegegn Woldermariam from WHO says their
biggest priority is making sure that the available vaccines are available for
everyone who needs them. He says for this to happen, what is available has to
be used sparingly.
//Cue in; “Currently there’s…
Cue out…of contacts.”//
WHO imported 8200 doses of the
vaccine to Uganda. So far, 8000 front line health workers, security personnel
and people believed to have been into contact with confirmed Ebola cases have
The shortage of the vaccines comes at a time when the Ebola
outbreak in the DRC is on the increase with over 2,700 cases reported. Over
200,000 people in DRC and its nine neighboring countries at risk have been
vaccinated using the vaccine.
Dr. Woldermariam says the existing stock of the vaccine can
be sufficient until next year when production of the next batch is expected if
there's no other major outbreak.
//Cue in; “For now we…
Cue out…epidemic behaves.”//
Dr. Woldermariam says despite the shortage of the vaccine,
with the provision of the Johnson and Johnson vaccine, no one would go without
//Cue in; “But as you…
Cue out…the country.”//
Health officials in the DRC have been against its use.
second experimental vaccine Ad26.ZEBOV/MVA-BN produced by Johnson & Johnson
necessitates two doses compared to the one for the Merck vaccine.
of the vaccine are currently being carried out by the Uganda Virus Research